VACCINATION FOR HIV AND AIDS

该计划项目是一项多学科的协调工作 旨在通过开发艾滋病毒-1疫苗预防艾滋病。 该提案涵盖了艾滋病毒-1毒株的重要问题 与SIV的变异性和交叉免疫原性，生产和 传统和新型HIV免疫原的组成、毒性 HIV特异性体液免疫和细胞免疫的检测和诱导 在小动物身上，以及对艾滋病毒候选疫苗的效力测试- 挑战黑猩猩。候选疫苗的选择 在黑猩猩身上进行的药效测试，以及可能扩大到人类使用的规模， 因此，应以系统、科学的方法为基础，包括 体液免疫和免疫应答的定量评估 豚鼠和恒河猴的细胞水平。具体的 本总体计划项目拨款提案的目标如下 以下是： 1)比较几种HIV-1毒株，根据以下条件选择 毒性的临床特征、生物学特性和血清分型 以及对豚鼠和恒河猴的免疫原性。 2)根据在目标1中获得的结果，开发候选艾滋病毒- 1疫苗制剂使用：a)灭活全病毒，b) 基因工程POL突变体，c)重组DNA包膜 和在酵母和哺乳动物细胞中表达的核心亚单位，以及d) 有效的佐剂。 3)测试最优HIV-1疫苗材料的效力和 根据上面获得的结果选择的协议，用于 对未感染的黑猩猩的HIV-1挑战的保护。 该计划项目由5个参与实验室组成 (项目一至五)在4个不同的机构，a)部 加州大学戴维斯分校医学院病理学 (UCD)(项目I)，b)肿瘤病毒实验室，癌症研究 加州大学旧金山分校(UCSF)研究所(项目 二)，c)加利福尼亚州埃默里维尔CHIRON公司(项目三)，d) 癌症研究所脂质体实验室(项目 四)和e)西南生物医学研究基金会，圣彼得堡 德克萨斯州安东尼奥(项目V)。我们相信这个财团会让 通过提供科学人才、独特的资源和 具备开展团队合作所需的行政能力 来完成所宣布的目标。

This Program Project is a multidisciplinary coordinated effort aimed at preventing AIDS through development of HIV-1 vaccines. The proposal encompasses the important issues of HIV-1 strain variation and cross-immunogenicity with SIV, the production and composition of conventional and novel HIV immunogens, toxicity tests and induction of HIV-specific humoral and cellular immunity in small animals, and efficacy tests of candidate vaccines in HIV- challenged chimpanzees. Selection of candidate vaccines for efficacy tests in chimps and possible scale up for human use will, thus, be based on a systematic, scientific approach including quantitative estimation of immune response on humoral and cellular levels in guinea pigs and rhesus monkeys. The specific aims of this overall Program Project Grant Proposal are as follows: 1) To compare several HIV-1 strains, selected on the basis of clinical features, biologic properties and serotyping, for toxicity and immunogenicity in guinea pigs and rhesus macaques. 2) Based on results obtained in Aim #1, to develop candidate HIV- 1 vaccine preparations using: a) inactivated whole virus, b) genetically engineered pol mutants, c) recombinant DNA envelope and core subunits expressed in yeast and mammalian cells, and d) effective adjuvants. 3) To test the efficacy of optimum HIV-1 vaccine materials and protocols, chosen on the basis of results obtained above, for protection against HIV-1 challenge in uninfected chimpanzees. This Program Project consists of 5 participating laboratories (Projects I-V) in 4 separate institutions, a) Department of Pathology, University of California, Davis, School of Medicine (UCD)(Project I), b) Tumor Virus Laboratory, Cancer Research Institute, University of California, San Francisco (UCSF)(Project II), c) Chiron Corporation, Emeryville, CA (Project III), d) Liposome Laboratory, Cancer Research Institute (UCSF)(Project IV), and e) Southwest Foundation for Biomedical Research, San Antonio, Texas (Project V). We believe this consortium makes sense by providing the scientific talent, unique resources and administrative competence to carry out the teamwork necessary to accomplish the stated objectives.